Dalen Meeter, Chief Financial Officer of Aspen Neuroscience, Inc. (NASDAQ:ASPE), filed a Form 3 initial statement of beneficial ownership on October 29, 2026, disclosing three stock option grants with no directly held common shares reported.

Key Highlights

  • Reporting person: Dalen Meeter, identified as Chief Financial Officer of Aspen Neuroscience, Inc.
  • No common shares reported: Table I, covering non-derivative securities, lists no directly or indirectly held common stock.
  • First option grant: 101,193 shares underlying a stock option with an exercise price of $8.70, expiring March 12, 2035, granted March 13, 2025.
  • Second option grant: 34,405 shares underlying a stock option with an exercise price of $5.74, expiring November 25, 2035, granted November 26, 2025.
  • Third option grant: 88,543 shares underlying a stock option with an exercise price of $5.74, expiring November 25, 2035, also granted November 26, 2025.
  • All options held directly by the reporting person, with vesting subject to continued service through each applicable vesting date.

Stock Option Details for Aspen Neuroscience's CFO Meeter Dalen

According to the filing, Dalen Meeter holds three stock options in Aspen Neuroscience, Inc., all classified as direct ownership. The first option covers 101,193 shares of common stock at an exercise price of $8.70 per share, expiring March 12, 2035. The filing states this option was granted March 13, 2025, with one-quarter vesting and becoming exercisable on March 10, 2026, and 1/48th vesting on the same day of each month thereafter, contingent on continued service.

The second option covers 34,405 shares at an exercise price of $5.74 per share, expiring November 25, 2035. According to the filing, this option was granted November 26, 2025, with one-quarter becoming exercisable on October 1, 2026, and 1/48th vesting monthly thereafter, subject to continued service. The third option covers 88,543 shares at the same exercise price of $5.74, also expiring November 25, 2035, and also granted November 26, 2025. The filing notes that 1/48th of this option vests on monthly anniversaries beginning December 20, 2025, again contingent on continued service.

No non-derivative securities are listed in Table I of the filing, meaning the reporting person disclosed no direct or indirect holdings of common stock at the time of filing. The form was signed by Jeffrey L. Boerneke as Attorney-in-Fact under a Power of Attorney (Exhibit 24), as indicated in the filing's remarks section.

What Was Disclosed

Dalen Meeter, CFO of Aspen Neuroscience, Inc. (NASDAQ:ASPE), filed an initial beneficial ownership statement reporting three stock options covering a combined 224,141 shares of common stock, with no directly held common shares disclosed.